Comparison between Mitomycin-C and Ologen Implants in the Treatment of Primary Open Glaucoma by Subscleral Trabeculectomy

Abstract Background Trabeculectomy was first performed in 1968 and is currently the greatest public glaucoma management method in the world (Cairns 1968). However, scarring and wound healing can lead to bleb fibrosis and drainage fistula occlusion, which can ultimately result in bleb failure. Methods A randomized approaching comparative interventional research was directed at 45 eyes of 40 participants 25 males and 15 females with primary open-angle glaucoma (POAG), Patients were distributed into three groups, Group A (included 15 eyes) of 13 participants who went through SST with adjuvant intraoperative usage of 0.2 mg/ml MMC, Group B (included 15 eyes) of 14 participants who underwent SST with a collagen matrix implant during surgery. Group C (included 15 eyes) of 13 participants who underwent SST with both a collagen matrix implant and MMC during surgery. Results The study showed no statistically significant variances among the groups concerning age, sex, eye laterality, glaucoma type, preoperative IOP, or the quantity of topical or systemic antiglaucoma medications prescribed. Systemic carbonic anhydrase inhibitors were used by six study participants. All of the eyes of the patients underwent straightforward trabeculectomy procedures, and the study group did not experience any implant-related intraoperative issues. Conclusion Based on these findings, we hypothesize that the Ologen implant could be a secure and reliable substitute for MMC in terms of enhancing the long-term efficacy of trabeculectomy surgery while avoiding the negative consequences connected to the application of supplementary therapy, such as MMC.